- Home
- INVE vs ASRT Comparison
INVE vs ASRT Comparison
Compare INVE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | ASRT |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 75.1M |
| IPO Year | 1997 | 1997 |
Fundamental Metrics
Financial Performance| Metric | INVE | ASRT |
|---|---|---|
| Price | $3.58 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.50 | $3.00 |
| AVG Volume (30 Days) | 49.3K | ★ 438.8K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $22,015,000.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $2.86 | $0.51 |
| 52 Week High | $4.29 | $1.01 |
Technical Indicators
Market Signals| Indicator | INVE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 47.26 |
| Support Level | $3.38 | $0.75 |
| Resistance Level | $3.79 | $0.80 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 60.85 | 74.57 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.